ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CPI Data Sparks Rally in Biotech Stocks

Biotech stocks

The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), experienced a significant breakout above a multi-year resistance level. The sector closed the week up a whopping 6%, compared to the overall market's 0.96% gain. This relative strength and significant outperformance following the inflationary data could set the tone for the remainder of the year.

Let's take a closer look at what caused this move, the overall sector, and several biotech stocks that made significant moves along with their sector.

CPI Data Sparks Biotech Rally

Inflation saw a significant decline last month, as revealed by the June Consumer Price Index (CPI) data released on Thursday. This development has led experts to suggest that the Federal Reserve might reduce interest rates more than once before the end of the year. June marked the first time prices fell in nearly two years, with the headline CPI dropping 0.1% month-over-month, the first decrease in 23 months, according to the U.S. Bureau of Labor Statistics. Economists had anticipated a 0.1% increase compared to May. On a yearly basis, CPI increased by 3.0% in June, down from 3.4% the previous month, surpassing the forecasted 3.1% rise.

Additionally, Core CPI, which excludes food and energy costs, also showed a lower-than-expected rise, increasing by only 0.1% in June from the previous month, whereas predictions had been for a 0.2% increase.

Why Is This Good for Biotech Stocks?

A cooling inflation rate can lead to lower borrowing costs, as the Federal Reserve might cut interest rates to stimulate the economy. For biotech companies, which often rely heavily on capital to fund their research and development pipelines, lower borrowing costs mean cheaper access to capital. This financial flexibility allows these companies to pursue growth and advance their drug development projects aggressively. The anticipation of more accessible access to funding likely contributed to the sector's strong performance and risk-on approach following the CPI data.

Sector Overview and Notable Movers

After the CPI data, the sector ETF (IBB) saw a significant breakout above a multi-year resistance level, closing the week up 6%. This breakout marks a potential shift in momentum for the biotech sector, which has lagged behind other market sectors. The IBB's $140 resistance has held firm since 2022; however, its close last week above this major resistance has confirmed a significant momentum and trend shift. The sector has been stuck in its post-pandemic lull and high-interest rate environment for several years. However, that all appeared to shift last week following the CPI inflation data and break above a multi-year resistance level.

Several biotech stocks made notable moves alongside the sector.

Regeneron Pharmaceuticals (NASDAQ: REGN): The largest holding of the IBB sector ETF with an 8.3% weighting, Regeneron led the sector last week, up almost 6.4%. This brings its year-to-date performance to over 25% and keeps it trading at 52-week highs.

Amgen (NASDAQ: AMGN): The fourth-largest holding of IBB, with a 7.99% weighting, Amgen closed the week up an impressive 6.42%. On Friday, AMGN broke out of a three-month consolidation and hit a new 52-week high.

Legend Biotech Corp (NASDAQ: LEGN): It wasn't only large-cap healthcare and biotech giants that outperformed last week. Small to mid-cap biotechnology companies also experienced notable surges and volume inflows. For example, shares of $9.9 billion biotech company Legend Biotech surged over 17% on the week after experiencing a significant uptick in trading volume on Friday and breaking above a multi-month consolidation.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.